|
Myocardial Infarction
|
0.090 |
Biomarker
|
disease |
LHGDN |
The aim of the study was to determine whether the alpha-adducin 460Trp variant allele modifies the risk-lowering effect of diuretics on myocardial infarction (MI).
|
19145769 |
2009 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to determine whether the alpha-adducin 460Trp variant allele modifies the risk-lowering effect of diuretics on myocardial infarction (MI).
|
19145769 |
2009 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We studied the risk of stroke, coronary heart disease (CHD), and myocardial infarction (MI) associated with the alpha-adducin variant and examined the extent to which this risk is modified by the presence of hypertension.
|
18458162 |
2008 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The risk of MI in current users of low-ceiling diuretics with one or two copies of the ADD1 W-allele (hazard ration (HR)=0.92) was similar compared to the expected joint effect of the W-allele and low-ceiling diuretics on a multiplicative scale (1.04 x 0.90=0.94) (synergy index (SI):0.99; 95% confidence interval (CI): 0.43-2.27).
|
17189961 |
2007 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Further, in contrast to reports from other investigators, we found little evidence for association of a C677T polymorphism in the 5,10-methylenetetrahydrofolate reductase gene, the angiotensin-I-converting enzyme 1 insertion/deletion polymorphism, a 4G/5G polymorphism in the serine/cysteine proteinase inhibitor-clade E-member 1 gene, the factor V Leiden mutation, the G20210A factor II mutation, a -455G>A polymorphism in the beta-fibrinogen gene, the cys112arg/arg158cys apolipoprotein E gene polymorphism, a gly460trp polymorphism in the alpha-adducin gene, and a -629C>A polymorphism in the cholesteryl ester transfer protein gene with risk of MI.
|
16420563 |
2006 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The alpha-adducin 460trp variant (OR 0.73, 95% CI 0.59-0.91, P=0.006) and the cholesteryl ester transfer protein -629A variant (OR 0.82, 95% CI 0.68-0.97, P=0.025) were both associated with a significant protective effect on MI, as was the paraoxonase 1/paraoxonase 2 haplotype comprising met55 and gln192 in paraoxonase 1 and cys311 in paraoxonase 2 (OR 0.52, 95% CI 0.39-0.77, P=0.001).
|
15039125 |
2004 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
These results show that in carriers of the 460Trp ADD1 allele (38% of the population), the administration of diuretics halves the incidence of myocardial infarction and stroke when compared with other antihypertensive treatments that produce similar reduction of BP.
|
14684671 |
2004 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
However, there is observational evidence that hypertensive patients with the 460 W allele of the alpha-adducin gene have a lower risk of myocardial infarction and stroke when treated with diuretics compared with other antihypertensive therapies.
|
15301563 |
2004 |
|
Myocardial Infarction
|
0.090 |
Biomarker
|
disease |
BEFREE |
To estimate the interaction between alpha-adducin and diuretic therapy on the risk of MI or stroke.
|
11926892 |
2002 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
LHGDN |
To estimate the interaction between alpha-adducin and diuretic therapy on the risk of MI or stroke.
|
11926892 |
2002 |
|
Myocardial Infarction
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In men in this study, the alpha-adducin polymorphism was not associated with the risk of myocardial infarction either among those with or among those without a clinical history of hypertension.
|
10723114 |
2000 |